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Gene Expression Profiles and Clinical Parameters for Survival Prediction in
Stage II and III Colorectal Cancer Patients

Mubeena Begum

ABSTRACT

Prediction of outcome in colorectal cancer (CRC) is currently based on the TNM staging
classification; however, histopathological classification alone is insufficient for accurately
predicting survival in stage II and III patients. Studies indicate that microarray gene
expression profiles can predict survival in CRC. We hypothesize that tumor gene expression
in combination with clinical parameters, is a better predictor of outcome in stage II and III
colorectal cancers than the TNM stage classification alone.
Clinical records and follow-up data were retrospectively reviewed for 58 Stage II and
Stage III patients with primary colorectal cancer, who did not receive any neoadjuvant
therapy preoperatively and whose samples had been previously analyzed for gene expression
profiles using the Affymetrix U 133a Gene chip. For molecular classification of patients as
being at high or low risk for poor survival, samples were divided into two clusters by
hierarchical cluster analysis of genes selected by SAM. Univariate and multivariate analyses
vi

using Cox proportional hazard models were done to identify significant prognostic factors
The 3-year and 5-year survival estimates were 72.41% (SE=5.8%) and 55.17%
(SE=6.7%), respectively, for all 58 patients. Univariate analysis showed that advanced stage,
older age, high-risk molecular classification, positive lymph nodes were the statistically
significant prognostic factors of poor survival (p<0.05), while gender, preoperative CEA
level, and family history of CRC in first degree relatives were not statistically significant. In
multivariate analysis molecular classification, age and body mass index were independent
significant prognostic factors. In Cox proportional hazard model, the estimated hazard ratios
for Stage III vs II was 2.45 (95%CI: 0.85-7.04), for high vs low molecular risk was 3.83
(95%CI: 1.22-12.06) and old vs young age was 3.72 (95%CI: 1.2-11.49). Model containing
clinical stage in conjunction with molecular risk, body mass index, and age was a stronger
indicator of clinical outcome (p= 0.0056) than model with clinical stage alone.
Gene expression profiles predict survival independent of clinical parameters, and the
addition of gene expression profiles to stage is more predictive of survival than stage alone.
Further analysis needs to be done to validate the molecular classification on an independent
dataset.
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CHAPTER ONE
INTRODUCTION

1.1 Background
Colorectal cancer (CRC), cancer of colon and rectum, the third most common cancer
worldwide and the second leading cause of cancer-related mortality in the US [1,2]. It is the
second most site-specific cancer affecting both men and women (lung cancer is first,
affecting both men and women, breast is the leader in women and prostate in men) [2]. The
lifetime probability of developing colon cancer in men is 1 in 17 and in women it is 1 in 18
[2]. A study conducted by Parkin, DM et al, 1999 [34] discusses that approximately, 6% of
the American population will eventually develop invasive CRC and over 6 million
Americans who are alive today will die of the disease. 75% of patients with CRC have
sporadic disease, with no evidence of having inherited the disorder and 25% have a family
history of CRC suggesting a genetic contribution.
Majority of the colorectal cancers arise due to malignant transformation of an
adenomatous polyp. The malignant tumor arises from colonic epithelial cells that line the
mucosa. Transition from normal epithelium to adenoma and to carcinoma is due to acquired
molecular events [1], that is, 85% of CRC are due to events which lead to chromosomal
instability (CIN) and 15% are due to microsatellite instability (MSI). These events alter
chromosomes 5q (APC), 18q (DCC) and 17p (TP53) involved in DNA repair.
1

1.2 Colon and Rectum: Structure and function
Colon refers to the upper six feet of the large intestine and rectum to the last five to six
inches. Together colon and rectum make up the large intestine. The colon is made of four
sections: ascending colon, transverse colon, descending colon and the sigmoid colon. Cancer
can develop in any of the four sections of the colon and in the rectum. The distributions of
colorectal cancer in the large intestine are: ascending colon and cecum-25%, transverse
colon-15%, descending colon-5%, sigmoid colon-25%, rectum-25% and rectosigmoid
junction-10% [43].
Tumors on the right side of the colon near the cecum usually grow large enough to be
painful and cause bleeding. As a result they commonly present with anemia from chronic
blood loss. Polyps commonly appear on the left side of the colon. Cancer on the left colon
usually grows around the colon wall and encircles it. Common symptoms of a tumor on the
left side include constipation and change in bowel habits. Cancer can grow inward toward
the hollow part of the colon or rectum, and /or outward through the wall of the colon or
rectum. In untreated cases the cancerous cells break away from the primary site and spread
to distant organs through bloodstream or lymphatic system. This process is called
metastases. 95% of CRC are carcinomas, and 95% of these are adenocarcinomas.
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1.3 Classification of Disease:
The currently used staging system for CRC is UICC-AJCC TNM staging system. The AJCC
TNM staging system is considered to be more useful for clinical decision-making, due to its
precise stratification. It consists of three independent prognostic variables: the depth of
tumor invasion into the bowel wall (T), the presence or absence of lymph node involvement
(N), and the presence or absence of distant metastases (M) [21, 53]. The pathologic staging is
assigned after the resection of the primary tumor, removal and examination of regional
lymph nodes and analysis of the surgical specimen. The AJCC/ UICC and Dukes’
classification system is shown in table 1. The survival rates for the different staging systems
are summarized in table 2.

Fig1. Anatomic Division and Tumor Penetration (AJCC 6th Edition System)
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Table1. AJCC/UICC Staging Sytem for Colon and Rectal Cancer
AJCC/UICC
Stage 0 and Tis

Description of AJCC Staging System
Carcinoma in situ: intraepithelial or invasion of the
lamina propria.

Dukes’

MAC

Stage I
(T1 N0 M0)

Tumor invades through the submucosa. No metastases
to regional nodes or distant metastases.

Dukes’ A

A

Stage I
(T2 N0 M0)

Tumor invades into the muscularis propria. No
metastases to regional nodes or distant metastases.

Dukes’ A

B1

Stage IIA
(T3 N0 M0)

Tumor invades through the muscularis propria into the
subserosa, or into non-peritonealized pericolic or
perirectal tissues, no metastases to regional nodes or
distant metastases.

Dukes’ B

B2

Stage IIB
(T4 N0 M0)

Tumor directly invades other organs or structures,
and/or perforates visceral peritoneum, no metastases to
regional nodes or distant metastases.

Dukes’ B

B3

Stage IIIA
(T1-2 N1 M0)

Tumor invades submucosa or muscularis propria.
Metastases in 1 to 3 regional lymph nodes. No distant
metastases.

Dukes’ C

C1

Stage IIIB
(T3-4 N1 M0)

Tumor invades through the muscularis propria into the
subserosa, or into non-peritonealized pericolic or
perirectal tissues or tumor directly invades other organs
or structures, and/or perforates visceral peritoneum.
Metastases in 1 to 3 regional lymph nodes. No distant
metastases.

Dukes’ C

C2/C3

Stage IIIC
(Any T, N2, M0)

Any extent of tumor invasion. Metastasis in 4 or more
regional. No distant metastases.

Dukes’ C

C1/C2/
C3

Stage IV

Any extent of tumor invasion or number of metastases
to regional nodes. Distant metastases present.

Dukes’ D

D
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1.4 Statement of Problem
Prediction of outcome is an important aspect in cancer research. In patients with colorectal
cancer limited to the mucosa (TNM Stage I) and in patients with distant metastases (TNM
Stage IV), the 5-year survival rates are 90-95% and <10%, respectively [2, 32]. In these
patients histopathologic criteria (TNM staging) are good predictors of survival. However, in
patients with invasion of the colon wall or adjacent structures (stage II) and those who have
regional nodal metastases (stage III), the probability of survival is about 70-85% and 40-80%
respectively based on the TNM staging [32]. Moreover, patients with same tumor stages
may show different prognosis indicating that conventional staging procedures may be unable
to precisely predict cancer risk. Thus, it is in stage II and III patients that a better predictor of
survival is needed. As an alternative to clinical staging, recently developed microarray
technology has permitted the development of multiorgan cancer classifier, identification of
tumor subclass, discovery of progression markers, and prediction of disease outcome in many
types of cancer. Unlike clinicopathological staging, molecular staging is able to better
predict the long-term outcome of an individual based on the gene expression profile of the
tumor at diagnosis [11].
Preliminary studies indicate that microarray gene expression profiles have been most
accurate to date in predicting the overall survival in CRC [11]. However, most research
examining gene expression profile has not taken clinical parameters (stage, age, sex, grade,
preoperative CEA levels) into consideration.

5

Table 2: 30 months and 60 months relative survival rate by AJCC sixth
Edition System [32].
Stage

30 months (%)

60 months % (5-year
relative survival rate)

Stage I

96.1

93.2

Stage IIA

91.0

84.7

Stage IIB

80.2

72.2

Stage IIIA

91.4

83.4

Stage IIIB

77.3

64.1

Stage IIIC

59.1

44.3

Stage IV

17.3

8.1

The 5-year survival rate refers to the percentage of people who live at least 5 years after their
cancer is diagnosed.

1.5 Study Purpose
The purpose of the study was to investigate whether clinicopathological (TNM staging)
based outcome (survival) prediction can be improved by combining microarray gene
expression profiles together with other clinical predictors (age, sex, grade, preoperative CEA
level).
Stage ----------Æ Survival
Stage+ GEP+ age + gender + body mass index (BMI)+ family history
+ location of tumor+ grade+ preoperative CEA level

--------------- Æ Survival

+ total resected lymph nodes
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1.6 Research Question:
1. What is the predictive value of traditional clinical predictors- age, sex, race, stage and
grade in determining prognosis (survival) in Stage II and III CRC patients?
2. What is the predictive value of gene expression profiles (GEP) by itself in this
sample?
3. What does the addition of GEP together with clinical parameters (age, sex, family
history, BMI, grade, location of tumor, preoperative CEA levels) contribute to the
usual clinical predictiveness of outcome (survival) in stage II and III colorectal
cancer?

1.7 Hypothesis
Gene expression profiles (GEP) and clinicopathological factors (age, sex, BMI, family
history, grade, preoperative CEA level) add to the predictive value of staging in predicting
the postoperative outcome (survival) in stage II and III CRC.

7

CHAPTER TWO

REVIEW OF LITERATURE

2.1 Descriptive Characteristics

Currently CRC constitutes 10% of new cancer cases in men and 11% new cancer
cases in women. Estimated new cases and deaths from CRC in the US in 2005 are 104,950
new cases and 56,290 deaths [2]. SEER data for 1998-2002 show the overall incidence of
CRC is higher in men (62.1/100,000) than in women (24.8/100,000), and this holds true for
mortality rates, in men (46.2/100,000) and women (17.4/100,000). The median age at
diagnosis in the United States, during this period is 70 for men and 74 for women.
Incidence is higher among African American men and women (62.4%) compared to
White men and women (52.5%), and so are the mortality rates in African Americans (20%)
to Whites (27.9%). The risk of CRC increases after the age of 50-55 years and continues to
rise exponentially with increasing age. Between 1998 and 2001, the incidence rate has
declined by 2.9% and 5-year survival rate has increased by 7.3%, which could be due to
advances in detection and screening and the increasing use of combination therapies [40].
Although the exact cause of CRC cancer is unknown, several factors play a crucial
role in the development and prognosis of CRC survival, which can be classified as prognostic
factors (tumor related, host related and environmental related factors) and risk factors.
8

Definition of Prognostic Factor: In epidemiological literature prognostic factor
refers to the probability of future event in patients who currently have a disease. It implies
prediction of an event that will occur in the future. It can be considered in the context of
probability of cure or prolongation of survival. Knowledge of prognostic factors helps us to
understand the progress of the disease [19].
Definition of a Risk Factor: “A clearly defined occurrence or characteristic that has
been associated with the increased rate of a subsequently occurring disease”. It is limited to
those who don’t have a disease [19].

2.2 Prognostic Factors
2.2.1 Tumor related prognostic factors
♦ Pathological staging: Is the most important predictor of outcome in patients with
newly diagnosed colorectal cancer [39, 52], which depends on the degree of
penetration of tumor through the bowel wall, presence of or absence of nodal
involvement and presence or absence of distant metastasis. Majority of the CRC are
adenocarcinomas.
♦ Histological grade: Tumor prognosis correlates with histological grade: poor
differentiation has a worse prognosis than a high degree of differentiation [39, 45].
Large studies have shown that histological grade correlates with survival and
recurrence, with low-grade tumors having better survival [21]. Venous, lymphatic and
perineural invasion have also shown to decrease survival and increase the risk of local
recurrence [21, 52].
9

♦ Surgical margins and radial margins: The presence of positive surgical or radial
margin is a poor prognostic factor, with local failure rate in all stages increasing from
3%-85% [37].
♦ Molecular markers: The use of molecular markers that have prognostic significance
aids in identifying high-risk patients who can benefit from adjuvant chemotherapy
and avoiding those who have low risk from the toxicities of adjuvant chemotherapy.
Presence of microsatellite instability has shown to improve prognosis in sporadic
colorectal cancers [20, 22]. Three studies have independently shown unfavorable
prognosis of patients with the loss of 18q in stage II and III CRC [24, 33, 41].
♦ Carcinoembryonic antigen (CEA): CEA levels are used to monitor the course of
colorectal cancer. Elevated pre-operative levels of CEA at diagnosis, has shown to be
an independent prognostic factor for survival and recurrence in CRC patients [21].
♦ Lymph nodes examined: AJCC and NCI recommend that at least 12 lymph nodes
should be examined in patients with colorectal cancer to confirm the absence of nodal
involvement by tumor [9]. It is a reflection of the aggressiveness of lymphovascular
mesenteric dissection during surgery and pathological identification of nodes in the
specimen. Retrospective studies have demonstrated that the number of LN examined
in CR surgery may be associated with patient’s outcome [47]. A study by Berger. A.
C et al., 2005, have demonstrated that lymph node resection is a statistically
important prognostic factor for determining overall survival and disease free survival.

2.2.2 Patient-related prognostic factors:
♦ Genetic Syndromes: Patients with Hereditary Nonpolyposis colorectal cancer
10

(HNPCC- is a familial syndrome in which individuals develop CRC before 50 years
of age), chronic ulcerative colitis (UC- inflammatory condition of the large intestine)
and Familial adenomatous polyposis (FAP- an autosomal dominant condition
characterized by multiple polyps with high potential to progress to cancer) are at
increased risk of colorectal cancer [51].
Hereditary Nonpolyposis Colorectal Cancer (HNPCC): Also called Lynch
Syndrome. It is an autosomal dominant condition caused by mutation in the DNA
mismatch repair genes (hMSH2, hMLH1). HNPCC accounts for about 3-5% of all
CRC [2]. They have increased risk of developing adenomas at an early age, the
average age of CRC diagnosis in HNPCC syndrome patients is around 44 years [2].
They also have an increased risk of developing other cancers such as endometrial,
ovarian, small intestine, pancreatic, renal pelvis and brain tumors.
Familial Adenomatous Polyposis (FAP): is an autosomal dominant condition with a
prevalence of 1/8,000 [2]. FAP is due to mutation in the APC gene on chromosome
5q21. The disease is characterized by hundreds of polyps in the colon and rectum,
which develop after the first decade of life. By the age of 20 and 30 the probability of
developing colonic adenoma increases by 75% and 90%, respectively [2].
♦ Familial Colon Cancer: A positive family history is an important risk factor
developing CRC. A two to three-fold increase in risk is seen if an individual has a
first degree relative with CRC and the risk increases if more relatives are affected
[40]. Family history of CRC is seen in 10-15 % of persons with CRC. This increases
the person’s risk to develop CRC by 2-6 fold. With a family history, the risk of CRC
increases earlier in life (less than 45 years) than later.
11

♦ Age: 3 % of the CRC arise before age of 30 years, and 11% have predisposing
conditions such as FAP and UC. The risk of CRC increases with age and it is most
common in men and women above 55 years. Studies have reported poor prognosis in
CRC patients who are less than 40 years [1]. Tumors with microsatellite instability
(MSI) have better prognosis irrespective of age [2].
♦ Racial difference: Racial differences in the overall survival were observed in few
studies although some studies have shown that co-morbid conditions play a role in the
survival outcome in different patient population. Jews of European decent have a
higher rate of CRC due to genetic mutation.
♦ Weight: Many studies have reported an increased risk of colorectal cancer with
increasing body mass index [10]. Having excess fat in the waist are (intra-abdominal
fat) increases the risk more than having the same amount of fat distributed in other
areas (thighs, hips). Obesity placed men more than women at increased risk for colon
cancer. This association in men is due to greater waist circumference in men and the
protective effect of estrogen in women, which decreases CRC risk. A study by
Giovanucci et al., 2001 [16] found a correlation between colon cancer and type-2
diabetes. Obesity predisposes a premenopausal woman to the same risk as does for
men in general [12].
♦ Geography: rates of colorectal cancer vary geographically. The disease is more
common among industrialized nations –USA, Western Europe, Australia and
uncommon in Asia, Africa and South America [48].
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Table: 3 Literature Review of Clinical and Pathological Factors Assessed by Cox Multivariate Analysis
Author, year

Study Features

Factors Analyzed

Findings and Strengths/Weakness

Bertucci, F et al. 2004
[5]

Prospective study
Single institution, France
Sample size: 50 samples
(26 patients) between
1990-1998.
All tumor sections and
Medical records were reviewed
prior to analysis.
Unsupervised hierchical
clustering was used to investigate
relationship between samples
and genes.

Gender, age, site of tumor, grade,
tumor penetration, LN involvement,
vascular invasion, stage, surgery,

Significance of prognostic classification made by AJCC
stage and the obtained gene set was compared.
Classification based on AJCC stage was significant but
less than that made by gene expression profiles.
prognostic impact of gene set persisted when applied to
patients without metastasis at diagnosis and patients
without metastasis and LN involvement.
Strengths: Accuracy of prediction of “molecular
metastatic signature’ was estimated by leave one
out procedure. DNA microarray was able to identify
clinically relevant tumor subgrous based on the gene
cluster.
Weakness: Multivariate analysis was not done to
determine significant clinical and pathological factors
affecting survival.

Barrier, A. et al., 2005
[3]

Prospective study
Sample size: 18patients
Stage II and II CRC patients
Follow-up:
Every 3 years-1st postoperative
thereafter.
year and every 6 months

Gender, stage, grade and location.
Prognostic prediction was build
based on microarray gene expression
measure for stage II and II CRC
patients. For each dataset a total
of 150 prognosis
predictors were considered and
Performance was assessed
using six-fold cross-validation.

70 gene predictor was built, 35 were overexpressed in
patients who developed a recurrence and 35 in patients
who were disease free for 5 years.
Strengths: Double cross validation was done by splitting
the data into testing and training set. The results of the
study suggest the ability to build a prognosis predictor
for both stage II and III CRC, based on either T or NM
gene expression profiles. The accuracy of the 70-gene
NM based predictor was greater than that of 30-gene
based predictor (83 vs 78%).
Weakness: The study did not analyze the effect of
Clinico pathological factor in association with gene
Expression profiles in predicting the survival.
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Author, year

Murphy T K et al. 2000
[31]

Study Features

Factors Analyzed

Findings and Strengths/Weakness

syndrome, cancer with IBD,
rectal cancers were excluded
because their molecular feature,
recurrence rate, and overall
differs from sporadic colon
cancers.

Dukes’ stage, grade, microsatellite
status, resected nodes, postoperative
complications, recurrence.
molecular and structural markersP53, P27, VEGF, microvessel count

regulation and Dukes’ stage, LN status. VEGF
overexpression correlated significantly with Dukes’ stage.
Strengths: Study compared levels of p53, p27, VEGF
and MVC, which are involved in cycle regulation,
apoptosis, and tumor neoangiogenesis, for normal
and colon cancer cells with clinopathological variables.
In conjuction with clinicopathological staging, molecular
Expression markers p27, p53, VEGF, provide a stronger
Indication of clinical outcome than with staging alone and help
better select therapeutic option in colorectal cancer patients.

Large prospective study
Population based, 50 States
Sample size: 1,184,659
Follow –up: 12 years
1616 final sample size
followinginclusion and
exclusion criteria

Age, sex, smoking and alcohol.
history, dietary history, exercise,
estrogen replacement therapy
and asprin use.
BMI was categorized for age
and gender.

The study was done to examine the association between BMI and
colon cancer mortality in both men and women. The findings in
the study were that BMI was an independent risk factor for colon
cancer death in both sexes and the relationship is stronger and
more linear in men than in women. This could be due to central
obesity causing hyperinsulinemia and increased glycemic load
causing tumor growth.
Alcohol intake significantly modified the association between
BMI and colon cancer mortality.
Strengths: Large prospective study, generalizeable to the
Population.
Weakness: lack of screening data, self reported measurements.
Did not look into other clinicopathological factors which affect
survival in CRC.
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Author, year

Study Features

Factors Analyzed

Findings and Strengths/Weakness

Ponz de Leon et al, 1992
[35]

Population based study
Sample size: 132
Follow-up: 5 years
Post operatively
Equal number of male
and female patient’s

Age, site of tumor, family history,
interval between diagnosis and
surgery, interval between symptoms
and diagnosis, stage, pattern of
growth, extent of fibrosis.

Factors which were significant in univariate analysis
analysis were: age, pattern of growth and extent of
fibrosis. However, the only significant factor related to
prognosis in multivariate analysis was stage.
Staging being the factor significant in multivariate
analysis confirms the importance of stage in predicting
survival in CRC.

Prall, F et al. 2004 [36]

Retrospective study with review
of clinical charts and medical
records.
Sample size: 184
All stages of CRC
Follow-up history was obtained
for 5 years postoperatively.

Clinical and immunohistochemical
tumor marker levels were estimated
(p53, p27, p21 levels).

In Cox multivariate analysis growth pattern of tumor,
lymphohistiocytic response, lymphatic permeation, and
extramural venous were found to be significant when
tested against UICC stage. Mitotic index added to the
prognostic information to TNM stage in multivariate
analysis.
Weakness of study: Effect of other prognostic markers
in combination with tumor markers (p53, p27, p21)
was not done on CRC patients in predicting survival.

Rene A. C. et al. 2004
[39]

Retrospective study
Sample size: 96 patients
From 1950 to 1990.
Follow-up: 3 years
All stages of CRC

Age, Gender, Karnofsky
performance at admission,
site of tumor, type of surgery,
preoperative albumin level,
number of resected organs/
structure, hospital stay, grade,
stage, lymph node status,
lymphatic invasion, perineural
invasion, tumor margins,
clinical presentation.

Study determine better survival (5-year) rate
for patients undergoing curative surgery (58.3%) than
palliative surgeries (0%).
Multivariate analysis showed Karnofsky performance
status was strongly related to the risk of postoperative
complications and postoperative deaths.
Factors which were related to better prognosis for CRC,
were grade I and II, non metastatic LN, absence of
vascular, lymphatic, perineural invasion,
Poor prognostic factors were lympn node status and
adjacent organ infiltration.
Strengths: A significant decrease of postoperative deaths
and complications from 1950 to 1990 could be due to
improvement in staging methods, pre and post operative and
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Author, year

Study Features

Factors Analyzed

Findings and Strengths/Weakness

Ratto, Carlo et al, 1998
[38]

Prospective study
Sample size: 853
Male and female patients
With CRC of all stages
Follow-up:
Every 3months-1st year
Every 6 months in 2nd-3rd year,
once per year thereafter

Gender, Age (</> 60 years)
Location of primary
history of bowel obstruction
Tumor size, Stage, Grade,
LN involvement, Metastasis,
Preoperative CEA, tumor ploidy
and vascular invasion.

Factors significant and independently influencing
outcome were gender, lymph node involvement,
history of metastasis and bowel obstruction.
Strengths: Large sample size and good power,
including tumor markers similar results were
observed in other studies too.
Weakness: Did not look into molecular markers
on survival prediction.

Wang et al. 2004 [50]

Retrospective study with review
of clinical charts.
Sample size: 74 Dukes’ B patients
Follow-up history for 3 years

Clinicopathological information was
collected. The sample was divided into
2 groups –testing and training set to select
gene markers using the training set and
build a prognostic signature and validate
it on the testing set.

The study demonstrates the potential of DNA microarray based
gene expression pattern for the prediction of patient’s outcome
in colon cancer. This is likely to have an impact on the current
clinical practice for the eligibility of adjuvant chemotherapy on
treatment of Dukes’ B colon cancer patients. The study
identified 23-gene signature that predicts recurrence in Dukes’ B
patients. The signature was validated in 36 independent patients.
The overall accuracy was 78%.
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CHAPTER THREE

METHODS

3.1 IRB Approval
Prior to the initiation of the research, the study was approved by the Institutional
Review Board (IRB) of the University of South Florida.

3.2 Study Design and Study Population
Retrospective cohort study with the review of clinical charts of 116 CRC patients;
who underwent curative surgery from 1/5/1993 to 5/1/2002, at Moffitt Cancer Center and had
a follow-up history up to the date of last contact or death.
Initial study started with the selection of 400 frozen tumor specimens of patients with
any of the four colorectal cancer tumor staging from Moffitt Cancer Center Tumor Bank
(Tampa, Florida); such that all patients had postoperative follow-up for at least 36 months
(because majority of patients who would die of CRC, will have done so by then) determined
by Moffitt Cancer Registry. The sample size was reduced to 116 as gene expression
profiling using mRNA technique was done to only 116 samples of the 400 CRC tumor
samples.
Retrospective review of inpatient charts, including operative and pathologic reports of
the 116 stages II and III CRC was done to obtain clinicopathological data. Data was
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collected on patient’s demographics, clinical, pathological and survival data. A copy of the
data entry form is provided in Appendix 1. Once the data was collected, in order to maintain
the patient confidentiality each patient was given a unique identification number generated
by SAS Randomisation. These data were entered on a standardized data entry form and
entered into a database. Based on the exclusion criteria the final sample size was reduced to
58 patients consisting of confirmed stage II or stage III primary colorectal cancer only.
3.2.1 Inclusion Criteria:
Confirmed Stage II and Stage III primary colorectal cancer patients, who did not receive any
neo-adjuvant therapy preoperatively and, who had a follow-up of at least 36 months and also
had gene expression profiling done using the mRNA technique.
3.2.2 Exclusion criteria:
As the study addressed only primary colorectal cancer 41 samples were excluded from the
116, who were Stage I or Stage IV colorectal cancer patients and also those for whom the
cancer site were not colorectal such as (abdominal wall, periaortic lymph nodes, mesenteric
lymph node, lung, liver, bladder, retroperitoneal lymph nodes, kidney, small intestine) after
reviewing the histopthological reports. Five patients had multiple primaries at the time of
surgery and were assessed by the histological grade to determine the earliest primary and
only the earliest primary was considered in the sample size and the others were excluded.
Nine patients who received preoperative neoadjuvant therapy such as radiated rectal cancers
were dropped from the study, as preoperative neoadjuvant therapy would affect gene
expression profiles, hence cannot be used as predictor. Histopathological information could
not be reconfirmed for three patients and were excluded from the sample size. Clinical and
histoathological characteristics of patients and their tumors are summarized in tables 6 and 7.
18

3.3 Gene expression profiles (GEP) and Molecular classification:
The Gastrointestinal Tumor Program, Bioinformatics and Biostatistics Core of
Moffitt Cancer Center and Research Institute performed the GEP of the 116 colorectal cancer
specimens.
The microarray data was analyzed using Significance Analysis of Microarrays
program (SAM) with censored survival data [11]. SAM identified genes most correlated with
survival time (3-year survival) and used permutation analysis to estimate the False Discovery
Rate (FDR). The first analysis was done for stage II and III CRC patients only. The data was
preprocessed using Robust microarray (RMA) and the censored survival time was calculated
for each sample. In this work, censoring occurred at time of last follow-up or for death in
which there was no evidence of disease. SAM was used to calculate genes that correlated to
survival time. A threshold yielding a 10% median FDR was selected, which resulted in 53
overexpressed genes. The analysis was repeated for cases of all stages (stage I, II, III, IV).
The data was again preprocessed using RMA and survival time was calculated. SAM was
again used to select genes. A median FDR of 2.5% (the minimum FDR possible) was
selected, resulting in 30 genes.
The gene expression for all 30 genes was extracted and the data was clustered. The
Gene Cluster 3.0 program for clustering and Java Treeview for visualizing the heatmap was
used. The genes were median centered and normalized prior to clustering. Hierarchical
clustering with the un-centered correlation similarity metric and complete linkage was used.
The resulting dendrogram can be seen below. This resulted in two main groupings (Clusters)
of the sample (columns) in the data, which were chosen as the “prognostic” groups for this
work. These groups were listed as Cluster 1(Low risk) and Cluster 2 (High risk) based on 3019

gene cluster. Cluster Analysis of 30 SAM selected genes were performed. Red color
represents over expressed genes relative to green, underexpressed genes.
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Fig 2. Dendrogram
3.4 Censoring
Patients were considered for censoring when incomplete information was available about
their survival time that is if they were lost to follow-up, alive with no evidence of CRC at the
date of last contact or who died but not due to CRC. Patients who did not die of CRC were
considered censored and patients who died of colorectal cancer at the end of the study were
considered as having experienced the outcome of interest (death) and were not censored.
3.5 Statistical Analysis
Univariate analysis and Kaplan-Meier procedure was done to find predictive value of each
prognostic variable. Multivariate analysis using stepwise selection procedure was done to
determine the effect of GEP in the presence of other clinical predictors. Final model
selection was based on factors which met proportional hazard assumption and/or had
biological or clinical significance.
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CHAPTER FOUR

DATA ANALYSIS

4.1 Descriptive Analysis:
A total of 58 patients matched the inclusion criteria for the study and all patients had
undergone curative surgery for cancer. Preliminary descriptive analyses were performed to
characterize the sample. Frequency and percentages for each variable were obtained
accounting for the missing values. Table 6 and 7 summarizes the clinical and pathological
characteristics of patients and their tumors.
Age at diagnosis was calculated as date of surgery minus the date of birth. Mean,
median and age range at diagnosis were determined. Age at diagnosis was divided into 3
groups: less than 50 years, 50-70 years and above 70 years. To further determine the
influence of advanced age on survival, age at diagnosis was divided into tertiles of upper 1/3
rd

age group and lower 2/3 rd age group.
Body mass index was calculated based on the height and weight at the time of surgery

of index primary colorectal cancer and divided into 4 groups: less than 18.5 (underweight),
18.5-24.5 (normal), 25-29.9 (overweight) and above 30 (obese). To further assess the effect
increased BMI on overall survival, BMI was divided into 2 groups: ≤ 25 and >25.
Location of primary cancer was merged into three groups: proximal colon (cecum,
ascending colon, hepatic flexure and transverse colon), distal colon (splenic flexure,
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descending colon and sigmoid colon) and rectum and rectosigmoid junction.
Tumor stage at the time of primary cancer was regrouped into two groups with Stage
IIA and IIB grouped as stage II, and stage IIIA, IIIB and IIIC grouped as stage III, because
there were very few patients in stage IIB and III A (table 6).
Mean and range of Lymph nodes taken at the time of resection of primary tumor were
determined and also grouped into ≤12 lymph nodes and greater than 12 lymph nodes.
Survival differences for regional lymph node (LN) involvement were assessed for:
No LN involvement, 1-3 group of LN’s, ≥ 4 group of LN. Further analysis was done by
collapsing the regional lymph node involvement into: lymph node positive group and lymph
node negative group.
Histological differentiation was categorized based on the grading: well-differentiated,
moderately differentiated and poor differentiation. Since, the number of patients in the welldifferentiated group were few, these patients were merged with patients with moderate
differentiation to compare survival with poor differentiated tumors. For preoperative CEA
level was divided into < 5ng/ml and >5 ng/ml.
Information on the vital status and cancer status at the date of last contact was
obtained through the Moffitt cancer registry and summarized in table 5.
4.2 Statistical Analysis
Once the descriptive analysis was performed on the study population, the research
questions were analyzed using SAS 9.0 software.
Survival distribution were estimated using the Kaplan-Meier procedure to assess the
influence of individual predictors (clinical parameters and GEP) on the overall survival of
patients in the study, to determine which parameters met the proportional hazard assumption
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and if there was significant difference between the strata for each parameter (predictor).
Univariate analysis was done to determine statistically significant prognostic factors, the
hazard ratios, confidence interval and p-values. Log-rank test was used to compare survival
estimates for each stratified variable. Log-rank test was employed to evaluate the null
hypothesis being tested that no overall survival difference exits between the strata for each
variable. Hypotheses were tested using p-values of 0.05 for statistical significance.
Multivariable analysis using stepwise Cox regression analysis was used to determine
independent significant prognostic variables. The likelihood ratio test based on maximum
partial likelihood estimates was used to eliminate confounding variables from the model.
Variables were considered eligible for removal if the likelihood ratio test significance level
was >0.05.
The final model contained factors that met the proportional hazard assumption and had a
biological or clinical significance in predicting colorectal cancer survival. Survival rates
were estimated by Cox proportional hazard model. Stepwise regression methods were used to
build statistical model for the association of prognostic factors with overall survival. Time
dependent hazard ratios were estimated. By observing HR, 95% CI for each factor, and the
change in the log likelihood statistic, it was ascertained which variables should remain in the
final model.
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CHAPTER FIVE

RESULTS

5.1 Descriptive Analysis
5.1.1 Demographic data
Table 6 displays the demographic (clinical) characteristics of the 58 CRC subjects in
the study.
The median survival time for the study sample was 75.36 years and the 3-year and 5year overall survival estimates were 72.41% (SE=5.8%) and 55.17% (SE=6.7%),
respectively (Fig 3).
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Fig 3 Kaplan Meier Curve for Overall Survival of the Study Population

24

Female patients had higher incidence rate of CRC (53%) than males (47%). In the
study sample, CRC was more commonly seen among Caucasians (81%), followed by African
Americans (4%) and Hispanics (2%). BMI of majority of the patients (58%) was above
normal (>25) at surgery. History of weight loss at the time of surgery was reported by 45% of
CRC patients. Positive family history for CRC in first degree relative was present in only 8
of the 58 patients.
Based on age, 10% were in the <50 years age group, 38% were 50-70 years age group
and 52 % were >70 years, at diagnosis. The median survival time for <50 years, 50-70 years
and >70 years at surgery was 4.8 years, 5.12 years and 3 years, respectively. Majority of the
individuals diagnosed with CRC were of the between 70-79 years of age (35%).

Age at Diagnosis

Percent (%)
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70-74

65-69

60-64

55-59

50-54

45-49

40-44

35-39

30-34

25-29

0

Years

Fig.4 Age distribution of the study population
At the end of 3 year follow-up 42 patients (72%) were alive and 16 patients were
dead (28%). At the date of last contact 29 patients (50%) were alive with no evidence of
cancer, 18 patients (31%) were dead with evidence of cancer, 4 patients (7%) died but with
no evidence of cancer and cancer status could not be ascertained for 7 patients (12%).
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Table 4 Survival Status at the end of 3-year follow-up
Vital Status

n

%

Alive

42

72

Dead

16

28

Table 5 Cancer Status at the Date of Last Contact
Cancer Status at Last Contact
Vital Status at
Last Contact
Alive (n=31)

No evidence of
Cancer
29

Evidence of
Cancer
0

Unknown

Dead (n=27)

4

18

5

2
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Table 6 Clinical Characteristics of Patients
Characteristics
Total Sample Size (n)
Age at Diagnosis, years
Mean
Median
Age Range
≤ 50 years
50-70 years
≥ 70 years
Upper 1/3rd Age group (≥ 74.75 years)
Lower 2/3rd Age group (< 74.75 years)
Gender
Female
Male
Race
Caucasian
African American
Hispanic
Asian
Other/Unknown
Body Mass Index
<18.5 (underweight)
18.5-24.9 (normal)
25.9-29.9 (overweight)
≥ 30 (obese)
Unknown
History of Smoking
Ever
Never
Unknown
Ever Female (n=31)
Ever Male (n=27)
Family History of Cancer
Present
Absent
Unknown
Family History of Colorectal Cancer
Present
Absent
Unknown

No. of
Patients
58

(%)

6
22
30
19
39

(10)
(38)
(52)
(33)
(67)

31
27

(53)
(47)

47
4
2
1
4

(81)
(7)
(3)
(2)
(7)

1
18
21
13
5

(2)
(31)
(36)
(22)
(9)

25
28
5
15
10

(43)
(48)
(9)
(48)
(37)

34
12
12

(58)
(21)
(21)

8
38
12

(14)
(65)
(21)

67.17 years
70.47 years
26.97 - 92.41
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5.1.2 Histopathological Characteristics:
Table 7 displays the histopathologic characteristics of the sample population as
described below.
The three most common site descriptions of CRC were sigmoid colon (27%),
ascending colon (25%) and rectosigmoid junction (17%). Based on the AJCC classification6th edition, in the study sample, 26% were stage IIA, 3% were stage IIB, 2% were stage IIIB,
14% were stage IIIB and 13% were stage IIIC colorectal cancers. Stage IIA and IIB when
combined together constituted 46% had Stage II CRC and stage IIIA, IIIB, IIIC when
combined together constituted 56% of colorectal cancers in the study. Of the patients
observed, 47% had no regional lymph node involvement, 29% had 1-3 group of regional
node positivity and 21% had more than 4 group of lymph node involvement.
Moderate differentiation of the tumor (76%) was the most common histological grade
in the sample population followed by poor differentiation (16%) and well-differentiated
tumor (7%). Pretreatment CEA levels were unknown for 59% of the patients. 17% had
preoperative CEA level more than 5 ng/ml and 24% had levels < 5ng/ml. Based on the gene
cluster analysis 47% were classified as low-risk group and 53% were of the high-risk
group.Other histological features observed were vascular invasion (13 patients), lymphatic
invasion (7 patients) and perineural invasion (3 patients). In addition to adenocarcinomatous
histology, mucinous histology of tumor was observed in 5 patients. Perineural, lymphatic
and vascular invasion was seen in 3 patients, 7 patients and 13 patients, respectively.
Resected margins were not clear of cancer after surgery with curative intent in 4 patients
only.
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Table 7 Histopathological Characteristics of Patients
Characteristics
Location of Primary
Proximal colon
Cecum & Ileocecal Valve
Acending colon
Hepatic flexure
Transverse colon
Distal Colon
Splenic flexure
Descending colon
Sigmoid Colon
Rectum and rectosigmoid junction
Rectosigmoid junction
Rectum
Stage
IIA (T3 N0 M0)
IIB (T4 N0 M0)
IIIA (T1-2 N1 M0)
IIIB (T3-4 N1 M0)
IIIC (Any T N2 M0)
Regional Lymph Node Metastasis
No Lymph node involvement (N0)
1-3 Lymph node involvement (N1)
≥ 4 Lymph node involvement (N2)
Could not be assessed (Nx)
Total Lymph Nodes Resected
Mean Lymph nodes resected
Range of Lymph nodes examined
≤ 12
>12
Grade/Differentiation
Well
Moderately
Poor
Unknown
Preoperative CEA* level
CEA ≥ 5.0 ng/ml
CEA < 5.0 ng/ml
Unknown
Molecular Classification
Low risk (Cluster 1)
High risk (Cluster 2)
Other Histological Features
Mucinous Histology
Signet Ring Histology
Perineural Invasion
Lymphatic Invasion
Vascular Invasion
Resected Margins Not Clear of Cancer

No. of Patients

(%)

21
2
15
0
4
20
0
4
16
17
10
7

(36)

(34)

(29)

26
3
2
14
13

(45)
(5)
(3)
(24)
(23)

27
17
12
2

(47)
(29)
(21)
(3)

13.63
2 - 35
28
30

(48)
(52)

4
44
9
1

(7)
(76)
(16)
(2)

10
14
34

(17)
(24)
(59)

27
31

(47)
(53)

5
0
3
7
13
4

* CEA: Carcinoembriyonic Antigen
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5.2 Statistical Analysis
The research questions are restated in this section to facilitate coherence and readability.
The first two research questions are stated as follows:
1. What is the predictive value of traditional clinical predictors- age, sex, race, stage and
grade in determining prognosis (survival) in Stage II and III CRC patients?
2. What is the predictive value of gene expression profiles (GEP) by itself in this
sample?

5.2.1 Univariate Analysis:
Table 8 lists the prognostic variables, their hazard ratios, 95% CI and p-values for the
comparisons of interest. 3-year and 5-year survival rates of the study sample are listed in
table 9.
General Hypothesis:
H0: No difference between the survival distribution for Group1 and Group 2, (S1 (t) =S2 (t)
for all t >0)
HA: There is difference in survival distribution between Group1and Group 2, (S1 (t) ≠ S2 (t)
for some t >0)
Where, Group1: Survival function S1 (t)
Group 2: Survival function S2 (t)
If the p-value < alpha (0.05) then H0 is rejected and concluded that group1 and group2 have
different survival distributions.
If p-value ≥ alpha, H0 is retained and conclude that there no sufficient evidence in the data
suggesting the opposite is true.
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A) TNM staging:

1.00

Stage 2 (n=29)

0.75

0.50
Stage 3 (n=29)
0.25

Log-Rank p = 0.0513
0.00
0

20

40

60

80

100

120

140

Survival in Months

Stage III
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68.97
75.86

43.97
67.65

0.77

2.17

0.0513

Fig 5 Kaplan Meier Survival Curves for TNM Staging of Tumor
H0: No difference between the survival distribution for stage III and stage II CRC, (S1 (t) =S2
(t) for all t >0).
HA: There is difference in survival distribution between stage III and stage II CRC, (S1 (t) ≠
S2 (t) for some t >0).
Patients with stage II CRC had better 3-year and 5-year survival rates compared to patients
with stage III CRC. The p-value < alpha (0.05) hence, H0 is rejected and concluded that
stage III and stage II patients have different survival distributions.
The hazard ratio for patients with stage III CRC was twice as high than that for
patients with stage II cancers.
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B) Molecular Risk:
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Fig 6 Kaplan Meier Survival Curves for Molecular Risk
H0: No difference between the survival distribution for high molecular risk patients and low
molecular risk patients, (S1 (t) =S2 (t) for all t >0).
HA: There is difference in survival distribution between high and low Molecular risk patients,
(S1 (t) ≠ S2 (t) for some t >0).
Patients of low molecular risk had better 3-year and 5-year survival rates compared to
patients of the high molecular risk cluster. The p-value < alpha (0.05) hence, H0 is rejected
and concluded that low molecular risk and high molecular risk patients have different
survival distributions.
According to this univariate analysis, the hazard for death for patients in the high-risk
gene expression group was double than that for patients in the low-risk gene expression
group and it is statistically significant.
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C) BMI:
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0.00041

Fig. 7 Kaplan Meier Survival Curves for BMI of Patients
H0: No difference between the survival distribution between patients with body mass index
>25 and <25, (S1 (t) =S2 (t) for all t >0).
HA: There is difference in survival distribution between between patients with body mass
index >25 and <25, (S1 (t) ≠ S2 (t) for some t >0).
Patients with BMI > 25 were found to have better survival and lower hazard for death
than patients with BMI <25 and an inverse relationship were seen between BMI and
mortality. The hazard for death for patients in the BMI >25 group was 32% lower than that
for patients in the BMI<25 group
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D) Age
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Fig. 8 Kaplan Meier Survival Curves for Age of Patients
Patients in the lower 2/3rd age group had better 3-year and 5-year survival rates and
lower hazard for death than patients who were in the upper 1/3rd age group. The p-value <
alpha (0.05) hence, H0 is rejected and concluded that older age group patients (upper 1/3 rd
tertile) have different survival distributions compared to younger patients (lower 2/3rd tertile).
The hazard for death for patients in the upper 1/3rd age group was double than that for
patients in the lower 2/3rd age group.
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Gender (HR: 1.58, p=0.2407), race (HR: 0.83, p=0.6932), family history of CRC
(HR: 0.79, p=0.6568), grade of tumor (HR: 1.42, p=0.4816), preoperative CEA levels (HR:
2.3, p=0.1461), location of tumor (HR: 0.73, p=0.2092), and total lymph nodes examined
(HR: 0.84, p=0.6607), were not statistically significantly associated with survival (Table 8).
Table 9 summarizes the 3-year and 5-year survival estimates of the study population
following surgery with curative intent based on the prognostic variable. Decreased survival
rates were observed for patients in the younger age group (<50 years) and the older age group
(>70 years) as compared to those in the middle age (50-70 years), with approximately 40-50
%, 5-year survival rate for patients in the young and old age group following diagnosis of
CRC.
Patients who were overweight and obese (BMI>25) at the time of surgery had better
survival rates compared to patients who were normal or underweight.
Higher survival rates at year 3 and year 5 were observed for patients in the low
molecular risk group as compared to those in the high risk group, which were statistically
significant. Specifically Stage 2 with low molecular risk and stage 3 with low molecular risk.
Patients with stage II CRC had better survival rates than Stage III patients and as
cancer progressed, the survival rates showed a trend with decreased survival with time.
Similar results were observed for lymph node involvement, with better survival rates for
patients with no nodal involvement as compared to <3 group and > 3 group of nodes positive
patients and survival rate decreased with time.
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Table 8 Univariate Analysis
Parameter
Estimate

ChiSquare

Hazard Ratio
(95% CI)

p-value

Stage
(Stage 3 vs Stage 2)

0.776

3.61

2.17 (0.98-4.8)

0.06

Molecular Risk –GEP
(High risk vs Low risk)

0.987

5.46

2.68 (1.2-6.15)

0.02

Age
(Upper 1/3rd vs Lower 2/3rd age group)

0.740

3.51

2.09 (0.9-4.5)

0.06

Gender (Female vs Male)

0.456

1.35

1.58 (0.7-3.4)

0.24

Race (Caucasian vs Other)

-0.183

0.16

0.83 (0.3-2.1)

0.64

BMI
(Overweight and obese vs Normal)

-1.150

7.45

0.317 (0.1-0.7)

0.006

Family History of Colorectal Cancer

-0.276

0.20

0.79 (0.2-2.6)

0.66

Grade/Differentiation
(Poor vs moderate and well)

0.352

0.49

1.42 (0.5-3.8)

0.48

Regional Lymph Node Involvement
(N1-N2 vs N0)

0.784

3.40

2.09 (0.9-5.0)

0.06

Location of Primary Tumor

-0.309

1.57

0.73 (0.5-1.2)

0.21

Preoperative CEA Level
(>5ng/ml vs <5 ng/ml)

0.834

1.99

2.3 (0.7-7.3)

0.16

Variable

CEA: Carcinoembriyonic antigen, GEP: gene expression profiles.
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Table 9: 3-year and 5-year Survival Estimates of the Study Population
Following Curative Surgery Based on the Prognostic Variable
Variable
Age
≤ 50 years
50-70 years
≥ 70 years
BMI
<18.5 (underweight)
18.5-24.9 (normal)
25.9-29.9 (overweight)
≥ 30 (obese)
>25
<25
Family History of CRC
Yes
No
Molecular Risk
Low
High
Stage
Stage II
Stage III

No. of
Patients

(%)

3-year survival
rate (%)

5-year survival
rate (%)

6
22
30

10
38
52

66.67
86.36
63.33

50
75.4
42.04

1
18
21
13

2
34
40
25

50
55.56
90
76.92

31.33
72.73
68.83

34
19

64
36

84.85
55

71.08
33.39

8
38

17
82

75
76.32

56

27
31

47
53

88.89
58.06

71.46
41.29

29
29

50
50

75.86
68.97

67.65
43.97

IIA (T3 N0 M0)
26
45
76.92
IIB (T4 N0 M0)
3
5
66.67
IIIA (T1-2 N1 M0)
2
3
50
IIIB (T3-4 N1 M0)
14
24
78.57
IIIC (Any T N2 M0)
13
23
61.54
Lymph Node Involvement
N0
27
48
77.78
N1
17
30
76.47
N2
12
21
58.33
Grade
Well
4
7
75
Moderately
44
77
77.27
Poor
9
16
55.56
Total LN Resected
>12
28
48
73.33
<12
30
52
71.43
NA*: Censored, LN: Lymph Node, CRC: colorectal cancer

67.57
66.67
50
48.21
38.46
68.87
51.73
33.33
NA*
55.24
44.44
57
50
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5.2.2 Multivariate analysis (Stepwise Model Selection):
Research Question
3. What does the addition of molecular classification (GEP) together with clinical
parameters (age, sex, family history, BMI, grade, location of tumor, preoperative
CEA levels) contribute to the usual clinical predictiveness of outcome (survival) in
stage II and III colorectal cancer?

General Hypothesis:
H0: βi =0 (no difference of covariates)
HA: βi≠0 (covariates influence survival)
where, βi is parameter estimate for multiple variables.
If p-value >0.05, then H0 is not rejected.

Is based on the Cox proportional hazard model: h (t,x) = h(t0) exp (β x).
This model allowed the estimation of the effect of each covariate in the presence of the
others. The hazard ratio for each variable is adjusted for the effects of all of the other
variables in the multivariate model.
The aim of the study was to establish whether GEP with clinipathological variables
provides better prognostic information for patients with stage II and III CRC in addition to
that afforded by staging alone.
In order to address this multivariate analysis using stepwise Cox Regression method
was used, with threshold of 0.05. Factors that were found to be significant in univariate
analysis were tested for independent statistical significance in multivariate analysis. Three
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prognostic variables: molecular risk, BMI and age were found to be independent predictors
of overall survival (Table 10). Staging of tumor was found to be statistically not significant
on multivariate model; however, it was retained in the final model in order to determine the
association of other factors in the presence of clinical staging of tumor. None of the other
variables were found to be significant. The likelihood ratio test based on maximum partial
likelihood estimates was used for eliminating confounding. The results of the multivariate
analysis for overall patient survival are shown in table 10.

Table 10: Significant Prognostic Risk Factors for Mortality (Overall Patient Survival)
Determined by Multivariate Analysis
Parameter
Estimate

ChiSquare

Hazard Ratio
(95% CI)

p-value

Stage
(Stage 3 vs Stage 2)

0.897

2.78

2.45 (0.85-7.04)

0.09

Molecular Risk –GEP
(High risk vs Low risk)

1.343

5.26

3.83 (1.22-12.06)

0.02

Age
(Upper 1/3rd vs Lower 2/3rd age group)

1.313

5.21

3.72(1.2-11.49)

0.02

BMI
(overweight and obese vs normal)

-1.22

5.78

0.29 (0.11-0.79)

0.016

Variable
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E. Multivariate analysis of Molecular Risk and Clinical Stage:
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58.33
89.34
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5-year rate (%)
77.04
50
65.63
36.84

Fig. 9 Kaplan Meier Survival Curves for Clinical Stage and Molecular risk combined.

According to fig 9, that there is difference in overall survival when molecular risk and
clinical staging were combined in multivariate analysis, and patients of the low molecular
risk group had better survival outcome than patients with high molecular risk group within
stage II and stage III clinical staging. Combining clinical stage with molecular risk
classification we were able to differentiate patients into different strata.
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5.2.3 Predictor Model
Factors, which were prognostically significant (biological or clinical) and met the
proportional hazard model by the assessment of log-minus log survival plot were included in
the final model. Stepwise procedure was used and based on the assessment of log likelihood
statistic final predictor model was selected.
Hypothesis:
Ho: Model with more variables (predicted model) is similar to the model with fewer
variables (basic model).
HA: The two models are different.

Basic Model: h (t,x) = h(t0) exp [(β1 (stage)
Predicted model: h (t,x) = h(t0) exp [(β1 (stage)+ β2 (molecular risk)+ β3 (age)+ β4(body mass
index)].

The Cox proportional hazard model: h (t,x) = h(t0) exp (β x), where, h(t0) is base line hazard
function, h (t,x) is hazard at time t, β is parameter estimate for the variable and x is value for
each variable denoted by “1” and “0” for presence and absence of the prognostic factor.

Based on the Cox Proportional Hazard Model the hazard ratios observed for stage, molecular
risk, age and body mass are:
h (t,x) = h(t0) exp [(β1 (stage)+ β2 (molecular risk)+ β3 (age)+ β 4(body mass index)].
h (t, stage III) = exp [(0.897* (1))+ (1.343* (0))+ (1.313*(0))+ (-1.22* (0))]= 2.4522;
h (t, stage III & high molecular risk) = exp[(0.897* (1))+ (1.343* (1))+ (1.313*(0))+ (-1.22* (0))]= 9.39;
h (t, stageIII & high mol risk & old age& BMI >25) = exp [(0.897* (1))+ (1.343* (1))+ (1.313*(1))+ (-1.22*
(1))]= 10.27;

The hazard ratio for stage alone= 2.452. And the addition of molecular risk to stage
increased the hazard to 9.39 and for the final model containing stage, molecular risk, age and
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BMI was 10.27. So, there is evidence that the advanced tumor stage (stage III), high
molecular risk, old age and body mass index >25 result in higher the hazard ratio and
decreased survival.
Predictor model with clinical stage, molecular risk, age and BMI was compared with
the model containing clinical stage alone. The test statistic is equal to the difference between
the –2LogL value in the model fit statistic for both models. The test statistic = 125.256112.659= 12.597, which is greater than Chi-square, 3 degree of freedom and at 95%
significance = 7.815.
By observing HR, 95% CI for each factor, and the change in the log likelihood
statistic, it was ascertained that clinical stage, molecular risk, age and BMI should remain in
the final model. Model containing clinical stage in conjunction with molecular risk, BMI,
and age was a stronger indicator of clinical outcome (p= 0.0056) than model with clinical
stage alone.

Fig.10 Survival Distribution for
Prediction Model with Stage

Fig.11 Survival Distribution for
Prediction Model Containing
Stage, Molecular Risk, Age and BMI
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CHAPTER SIX

DISCUSSION

6.1 Important Findings
The mean age at diagnosis was 67.17 years (SE= 14.32%). The median age was
observed to be 70.47 years, and the age range at diagnosis was 26.97 to 92.41 years. 33% of
patients were in the upper 1/3rd age tertile and 67% were in the lower 2/3rd age tertile. The
median survival after surgery for Stage IIA and IIB was 4.6 and 5 years, respectively. And
for stage III A, IIIB and IIIC the median survival was 3.7, 4.5 and 4.2 years, respectively.
The median survival in years following surgery for the low molecular risk group was 4.9
years and 4.1 years for the high risk group.
The risk of mortality increased with advance in tumor stage and with age. A
progressive decrease in 5-year survival rates was evident as cancer progressed from TNM
stage II A to stage IIIC (table 9). Low molecular risk patients had better survival outcome
and 5-year survival rates compared to high molecular risk patient.
The inverse relationship seen with between BMI >25 and mortality could be due to
the fact that most patients were overweight before cancer diagnosis and had significant
weight loss from the time of diagnosis to surgery at which time BMI was recorded and were
less healthy due to cancer. Hence, BMI <25 indicates significant weight loss in these
patients and poor survival rates due to advance in cancer, co-morbid condition and poor
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immune status. Patients with BMI >25 at surgery had 32% lower hazard for death than
patients with BMI<25.
Although, family history of CRC did not show to be significantly associated with
poor outcome, information on history of CRC in the family and the size of the patient cohort
may be insufficient to identify positive family history of CRC as a prognostic factor in this
study. A larger patient cohort will be required to definitely determine whether family history
of CRC at diagnosis improves the accuracy of outcome prediction.
Significant difference in survival outcome was not observed based on the race,
because majority of the patients in the study were Caucasians and could not be generalized to
the population. Grade, an important factor in survival prediction was not found to be a
statistically significant prognostic factor, as has been reported in previous studies. In some
studies significant difference in survival was seen for preoperative CEA level, lymph node
resection, regional lymph node involvement, however, in this study no significant difference
in survival was observed.
Univariate analysis of the study showed 4 out of 10 variables were statistically
significantly associated with overall survival (table 8). Among the clinical variables
analyzed, gene expression profiling analysis distinguished two groups with significantly
different survival outcomes (high risk vs low risk, HR: 2.68, p=0.0151, fig6). Borderline
statistical significance was observed for TNM staging of tumor (stages III vs II, HR: 2.17,
p=0.0513, fig5). The strong measure of association indicates that the significance is not due
to chance alone.
Being older (>74.27 years) doubled the hazard for death compared to those younger
(<74.25 years). Patients with BMI > 25 were found to have better survival and lower hazard
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for death than patients with BMI <25 and an inverse relationship were seen between BMI
and mortality. The hazard for death for patients in the BMI >25 group was 32% lower than
that for patients in the BMI<25 group (Table 8). The hazard ratio for patients with lymph
node involvement was two times higher than patients without nodal involvement.
The purpose of the study was to investigate the hypothesis that combined assessment
of clinicopathological factors and gene expression profiles will allow increased accuracy of
survival prediction for patients with CRC over the use of staging alone. A significant
difference in survival was observed between the starta when staging and molecular risk were
combined (p=0.0301, fig 9).
In this study it was found that GEP (molecular risk) are powerful predictors of
survival independent of clinicopathological predictors. Stage, molecular risk, age and body
mass index, have been identified as significant prognosticators of survival in this study.
Combining molecular classification, BMI and age of patients to clinical staging, was a better
indicator of clinical outcome than clinical staging alone.
Four prognostic variables: TNM staging, molecular risk, BMI and age were found to
be independent predictors of overall survival in multivariate analysis.

6.2 Strengths and Weakness of the study:
Strength: Study had highly specific inclusion and exclusion criteria and limited to only
primary colorectal cancer of stage II and III patients. All surgical and pathology reports for
the study population were individually verified. To minimize error due to case abstraction,
majority of the patient’s charts were reviewed by same individual and for the few patients
whose history was abstracted by other abstractors, the information collected by them was
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cross validated. Certain risk factors that could affect the survival were controlled for in this
study in multivariate analysis by stratifying the variables based on presence or absence of the
risk factor (postmenopausal hormone use, smoking history, alcohol history). In the study
only 10% of the patients were lost to follow-up. This type of study is useful to obtain
information on colorectal cancer disease patterns over time and associate such patterns to the
distribution of time to death among patients diagnosed with colorectal cancer. A study of
this nature can be applied to public health practice by identifying factors that are important in
cancer control and intervention, which can minimize mortality and morbidity by screening
procedures and early diagnosis and treatment among the general population.
The study was able to determine the contribution of gene expression profile as a
predictor along with other parameters in survival prediction in colorectal cancer patients.
Weakness: The study is a retrospective cohort study from which information on patient’s
demographics and histopathological characteristic were gathered, which could contribute to
misclassification. Due to the small sample size the study lacked power and hence significant
differences in survival outcomes for certain prognostic variables such as preoperative CEA
levels, grade and smoking and alcohol history, could not be determined. Cancer status at the
end of follow up was ascertained from Moffitt Cancer Registry. Since 7 patients were lost to
follow up and this is related to outcome (survival) and this could have caused attrition bias in
the study. It is possible that differential misclassification of tumor stage and cause of death
could have occurred either by recording deaths from other causes as deaths from colorectal
cancer or vice versa.
Since most patients were Caucasians the results of this study cannot be generalized to
the general population, as the study sample does not represent the population in general. The
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influence of confounding factors such as smoking and alcohol consumption could not be
determined in this study, as detailed information could not be obtained from clinical charts.
Other factors, which could modify the risk of developing CRC such as diet, postmenopausal
hormone use and physical activity, were not taken into consideration because of inadequate
information. Certain factors that could influence survival outcome such as body mass index
at the baseline (before cancer diagnosis) and the effect of treatment following surgery were
not taken into consideration during data analysis.

6.3 Consistency with literature:
As in this study; similar results were seen in other studies that identified stage,
molecular risk and age as significant prognosticators of survival. Data from literature and
present study suggest clinical parameters, particularly stage [9, 39, 52], molecular risk
[11,20, 22], age [1,2, 31] and body mass index [12,16,27] are related to patient survival rate
and are most reliable prognostic factors.
Prognostic factors that were found to be significant in other studies but were not
significant in this study were family history [2, 40], histological grade of tumor [21, 39, 52],
and preoperative CEA levels [21, 30]. Differences between our study and others are mostly
due to differences in the number of patients, lack of power, length of follow-up, and grouping
of continuous variables also because the influence of comorbid conditions on survival which
could not be analyzed in this study, family history, personal history of cancers, dietary
history, multivitamin use, physical activity, screening history were not taken into
consideration because of inadequate information.
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6.4 Conclusion
Because of the frequency of the disease, the ability to identify high risk groups, better
survival of patients with early-stage lesion, and the relative simplicity and accuracy of the
screening tests, screening for colon cancer should be part of routine care for all adults at the
age of 50 years, especially those with family history of colorectal cancer. Periodic evaluation
following treatment of CRC helps to identify and manage recurrent disease.

6.5 Public Health Importance:
Colorectal cancer presents a major health problem with an annual estimated incidence rate of
106,680 new cases of colon cancer and 41,930 rectal cancers in 2006 and together they will
cause 55,170 deaths in the US. Due to the long natural history of cancer there is time for
early diagnosis and treatment before it reaches an advanced and incurable stage.
Since CRC is highly treatable and detected early, effective preventive approaches
help reduce the morbidity and mortality associated with due the disease. Removal of
premalignant lesion (adenoma) at the time of screening (colonoscopy) may be an effective
form of primary prevention.
Certain behavioral factors which modify the risk of developing CRC such as dietary
habits, physical activity, alcohol and cigarette smoking represent potential means of
prevention.
According to the ACS a guideline listed in Appendix 2, screening helps in early
detection and reduces the risk of dying from CRC. People who have no identifiable risk
factors (other than age) should begin regular screening at the age of 50 years. Those who
have a family history or other risk factors for CRC polyps or cancer should start screening at
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a younger age and more frequently.
Following diagnosis and treatment for persons with CRC, periodic evaluation by
monitoring preoperative CEA levels, aids in earlier identification and management of
recurrent disease and cancer progression.

6.6 Future directions
For future studies it will be important to validate the gene expression cluster obtained
in this study and the predictor model on an independent dataset. To conduct a prospective
study of a larger sample size and include people of differences in ethnicity, study the
prognostic ability of GEP and other factors such as family history, comorbid conditions,
treatment following surgery, histopathological features (p27, p53, VEGF), vascular,
perineural and lymphatic invasion and the influence of comorbid conditions on outcome
prediction. Analyze the interaction between clinicopathological factors and GEP and other
outcome measures such as time to relapse and treatment response. To determine if
differences exists in CRC survival on the basis of screening between those persons who
underwent regular screening and those who did not undergo regular screening as
recommended by the American Cancer Society.

49

List of References

1. National Cancer Institute (NCI), 2005
2. American Cancer Society: Cancer Facts and Figures 2005. Atlanta, GA., 2005
3. Barrier, A. and S. Dutoit (2005). "Colon cancer prognosis prediction by gene
expression profiling." Oncogene 24: 6155-6164.
4. Berger, A. C. and e. al (2005). "Colon Cancer Survival is associated with decreasing
ratio of metastatic to examined lymph nodes." J Clin Oncol 23(34): 8706-12.
5. Bertucci, F., S. Salas, et al. (2004). "Gene expression profiling of colon cancer by
DNA microarrays and correlation with histoclinical parameters." Oncogene 23: 13771391.
6. Bostcik, R., J. Potter, et al. (1993). "Reduced risk of colon cancer with high intake of
vitamin E: the Iowa womens' Health Study." Cancer Epidemiol Biomarkers Prev
5(11): 897-900.
7. Charlson, M. E. and R. C. MacKenzie (1987). "A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation." J Chron
Dis 40(5): 373-383.
8. Concato, J. and A. R. Feinstein (1995). "Importance of events per independent
variable in proportional hazards analysis. Background, goals, and general strategy." J
Clin Epidemiology 48(12): 1495-1501.
9. Compton CC, Greene FL (2004): The staging of colorectal cancer: 2004 and beyond.
CA Cancer J Clin 54 (6): 295-308.
10. Doria-Rosa, V. P. et. al (2006). "Body mass index and the risk of death following the
diagnosis of colorectal cancer in postmenopausal women (United States)." Cancer
Causes and Control 17: 63-70.
11. Eschrich, S. and T. J. Yeatman (2005). "Molecular staging for survival prediction of
colorectal cancer patients." Journal of Clinical Oncology 23(15): 3526-3535.
12. Frezza, E. E., M. S. Wachtel, et al. (2006). "Influence of obesity on the risk of
developing colon cancer." Gut 55: 285-291.
50

13. Friedenreich, C. (2001). "Physical activity and cancer prevention: from observational
to intervention research." Cancer Epidemiol Biomarkers Prev 10(4): 287-301.
14. Fuchs, C., E. Giovannucci, et al. (1999). "Dietary fiber and the risk of colorectal
cancer and adenoma in women." N Engl J Med 340(3): 169-76.
15. Galizia, G., E. Lieto, et al. (2004). "Determination of molecular marker expression
can predict clinical outcome in colon carcinomas." Clinical Cancer Research 10:
3490-3499.
16. Giovannucci, E. (2001). "Insulin, Insulin -like growth factors and colon cancer: a
review of the evidence." J. Nutr 131: 3109-20s.
17. Giovannucci, E., D. Nikolova, et al. (1998). "Multivitamin use, folate and colon
cancer in women in the Nurses' Health Study." Ann Intern Med 129(7): 517-524.
18. Giovannucci, E., E. Rimm, et al. (1994). "Aspirin use and the risk for colorectal
cacner and adenoma in male health professionals." Ann Intern Med 121(4): 241-246.
19. Gospodarowicz, M. K., D. E. Henson, et al. (2001). Prognostic Factors in Cancer.
New York, A John Wiley & Sins, inc.
20. Gryfe, R. and H. Kim (2000). "Tumor microsatellite instability and clinical outcome
in young patients with colorectal cancer." N Engl J Med 342: 69-70.
21. Guerra, A. and F. J. Jimenez (1998). "Multivariate analysis of prognostic factors in
resected colorectal cancer: A new prognostic index." Eur J Gast Hepatol 10: 51-8.
22. Halling, K. and A. French (1999). "microsatellite instability and 8p allelic imbalance
in stage B2 and C colorectal caners." J. NAtl Cancer Inst 91: 1295-1303.
23. Iwatsuki, S. and T. E. Starzi (1999). "Hepatic resection for metastatic colorectal
adenocarcinoma: a proposal of a prognostic scoring system." Journal of American
College of Surgeons 189(3): 291-299.
24. Jen, J. and H. Kim (1994). "Allelic loss of chromosome 18q and prognosis in
colorectal cancer." N Engl J Med 331: 213-21.
25. Johnston, P. G. (2004). "Of what value genomics in colorectal cancer? Opportunities
and challenges." Journal of Clinical Oncology 22(9): 1538-1539.
26. Kampman, E. and E. Giovannucci (1994). "Calcium, Vitamin D, dairy foods and the
occurrence of colorectal adenoma among men and women in two prospective
studies." Am J Epidemiology 139(1): 16-29.
27. Kune, G., S. Kune, et al. (1990). "Body weight and physical activity as predictors of
colorectal cancer risk." Nutr Cancer 13(1-2): 9-17.
51

28. Longley, D., D. Harkin, et al. (2003). "5-Fluorouracil: Mechanism of action and
clinical strategies." Nat Rev Cancer 3: 330-338.
29. Mackillop, W. J. and C. F. Quirt (1997). "Measuring the accuracy of prognostic
judgement in oncology." J Clin Epidemiology 50(1): 21-29.
30. Moertel, C. and V. Go (1986). "The preoperative carcinoembriyonic antigen test in
the diagnosis, staging and prognosis of colorectal cancer." cancer 58(603).
31. Murphy, T. K. and e. al (2000). "Body mass index and colon cancer mortality in large
prospective study." Am J Epidemiology 152(9): 847-854.
32. O'Connell, J. B., M. A. Maggard, et al. (2004). "Colon cancer survival rates with the
new American Joint Committee on Cancer sixth edition staging." Journal of the
National Cancer Institute 96(19): 1420-1425.
33. Ogunbiyi, O. and P. Goodfellow (1998). "Confirmation that 18q allelic loss in colon
cancer is a prognostic indicator." J Clin Oncol 16: 427-33.
34. Parkin, D., P. Pisani, et al. (1999). "Global cancer statistics." CA Cancer J Clin
49(33).
35. Ponz de Leon et al. (1992). "Clinical and pathological prognostic Indicators in
Colorectal Cancer". Cancer 69: 626-635.
36. Prall, F. and e. al (2004). "Expression Profiling of Colorectal Carcinomas Using
Tissue Microarray: Cell Cycle Regulatory Proteins p21, p27, and p53 as
Immunohistochemical Prognostic Markers in Univariate and Multivariate Analysis."
Applied Immunohistochemistry and Molecular Morphology 12(2): 111-121.
37. Quirke, P. and P. Durdy (1986). "Local recurrence of rectal adenocarcinoma due to
inadequate surgical resection. Histopathological study of lateral tumor spread and
surgical excision." Lancet 1: 996-999.
38. Ratto, C. and F. Crucitti (1998). "Prognostic factors in colorectal cancer. Literature
review for clinical application." Dis Colon Rectum 41(8): 1033-49.
39. Rene A.C. et al (2004). "Prognostic factors in locally advanced colon cancer treated
by extended resection". Rev. Hosp. Clin. Med. S. Paulo 59(6): 361-368.
40. Sandler, R. S. (1996). "Epidemiology and risk factors for colorectal cancer."
Gastroenterology Clinics of North America 25(4): 717-734.
41. Shibata, D. and M. Reale (1996). "The DCC protein and prognosis in colorectal
cancer." N Engl J Med 335: 1727-32.
42. Slattery, M., M. Schumacher, et al. (1988). "Physical activity , diet, and risk of colon
cancer in Utah." Am J Epidemiology 128(5): 989-99.
52

43. Sleisenger, M., M. Feldman, et al. (2004). Gastrointestinal and Liver diseases,
Pathophysiology/ diagnosis and management, Saunders.
44. Society, A. C. (2005). "Cancer Facts and Fiures."
45. Steinberg, S. and K. Barwick (1986). "Importance of tumor pathology and
morphology in patients with surgically resected colorectal cancer." cancer 58: 1340.
46. Strumer, T., R. Glynn, et al. (1998). "Aspirin use and colorectal cancer: post-trial
follow-up data from the Physicians' Health Study." Ann Intern Med 128(9): 713-20.
47. Tepper JE, O'Connell MJ, Niedzwiecki D, et al.(2001): Impact of number of nodes
retrieved on outcome in patients with rectal cancer. J Clin Oncol 19 (1): 157-63.
48. Trichopoulos, D. and e. al (1997). Epideimiology of Cancer. Philadelphia, LippincottRaven.
49. Vieira, R. A. C. and C. A. Melo (2004). "Prognostic factors in locally advanced colon
cancer treated by extended resection." Rev. Hosp.Clin. Fac. Med 59(6): 361-368.
50. Wang, Y., T. Jatkoe, et al. (2004). "Gene expression profiles and molecular markers
to predict recurrence of Dukes B colon cancer." Journal of Clinical Oncology 22(9):
1564-1571.
51. Watson, P. and K. Lin (1998). "Colorectal carcinoma survival among hereditary
nonpolyposis colorectal carcinoma family members." Cancer 83: 259.
52. Wolmark, N. and B. Fisher (1986). "the prognostic value of the modification of the
Dukes' C class of colorectal cancer." Ann Surgery 203: 115.
53. Wolters, U. and H. W. Keller (1996). "Colorectal cancer- A multivariate analysis of
prognostic factors." Eur J Surg Oncol. 22: 592-7

53

APPENDIX 1

Colorectal Cancer Prevention
Colorectal cancer occurs as a result of complex interaction between a person’s inherited
susceptibility (genetic) and environmental factors. Epidemiological and clinical
investigations suggest that diet high in fat, calories, protein, alcohol and meat and low in
calcium and folate are associated with increased with increased incidence of CRC.
Modifiable factors:
♦ Diet: Diet high in fat, meat (both red and white), alcohol and low in calcium and folate
are associated with increased incidence of CRC. Evidence on whether diet high in fiber
exerts a protective role in reducing the incidence of CRC is mixed. A high-fiber diet is
thought to be protective, because it accelerates the rate at which fats pass through the
bowel and reducing the exposure/contact of the large intestine to carcinogens [26, 40].
However, conflicting results are seen in some studies.
♦ NSAIDS: Some studies reported a reduction in colon cancer incidence with the use of
aspirin, with a 30% overall reduction in colorectal cancer, including a 50% reduction in
advanced cases [18]. However, in a follow-up study there was no association between the
use of aspirin and the incidence of CRC [46]. The use of NSAIDS as a primary
prevention measure is being considered and will depend on the dose and duration of
intake.
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♦ Cigarette smoking: Cigarette smoking is associated with an increased tendency to form
adenomas and develop into colorectal cancer [2]. Most case control studies of cigarette
exposure and adenomas have found an elevated risk for smokers. In the Cancer
Prevention study II, a large nationwide cohort study, multivariate-adjusted colorectal
cancer mortality rates were highest among current smokers, intermediate among former
smokers, and lowest in never smokers, with increased risk after 20 or more years of
smoking history among both men and women. Based on this study data, it was estimated
that 12% of colorectal cancer deaths in the US population in 1997 were attributable to
smoking (Chao, A et al, 2000). A positive relationship between alcohol intake and large
bowel cancers was seen in some studies [10].
♦ Vitamins: An inverse association was found between the risk of CRC and intake of
vitamins E; the RR for the highest compared to the lowest quartile was 0.3 (95% CI,
0.19-0.54) [6]. A similar association was seen for Vitamin D and folic acid intake and
risk of CRC [17].
♦ Calcium: Several studies have observed an inverse relationship between calcium intake
and cancer risk. Orally ingested calcium binds with bile acids and fatty acids released
into the intestine following a high fat diet, to form insoluble compounds which are not
harmful to the colonic mucosa and thereby reduces the exposure to the toxic effects of
bile acids [43].
♦ Post menopausal female hormones: Epidemiologic Studies have suggested a decreased
risk of colon cancer among users of postmenopausal female hormone supplements [10]
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♦ Physical activity: An inverse relationship is seen between level of physical activity and
colon cancer incidence. A sedentary lifestyle has been associated with an increased risk
of colorectal cancer in some studies [13, 44] but not all [27].
♦ Colonscopy: Colonscopy with the removal of adenomatous polyps helps in reducing the
risk of CRC.
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APPENDIX 2
ACS Screening Guidelines
Beginning at age 50, men and women should have 1 of the 5 screening option below:
1. A fecal occult blood test (FOBT) or fecal immunochemical test (FIT) every year
2. Flexible sigmoidoscopy every 5 years
3. FOBT/FIT every year plus sigmoidoscopy every 5 years
4. Double contrast barium enema every 5 years or
5. Colonoscopy every 10 years.
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APPENDIX 3
CLINICAL CHART REVIEW DATA ENTRY FORM
Note:

Dates are entered in MM/DD/YYYY format.
If month or day is unknown, specify value as 01.
If entire date is unknown, specify value as 01/01/1111
2.

3-4.

Moffitt medical record number
Tissue for study:
Note: This tissue should be the
earliest colorectal primary; if
colorectal primary tissue not
available, then earliest available
other site

5.

Date of collection

6.

Surgical Accession Number

7.

Gender

8.

Race/ethnicity

9.

Date of birth (MM/DD/YYYY)

1
2
3
4
5
6
7

First colorectal primary
Second colorectal primary
Local recurrence
Appendiceal adenocarcinoma
Hepatic metastasis
Pulmonary metastasis
Other metastasis:
Site _________________________
/

(4)

/

S - ______________________
0

Male

1

Female

1 Caucasian
2 African American
3 Hispanic
4 Asian
5 Other/unknown
/

/
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10-18.

Clinical presentation with
index primary colorectal
cancer:
None recorded
Asymptomatic
Melena
Hematochezia
Change in bowel habits
Abdominal pain
Weight loss
Clinically “Obstructed”

0
0
0
0
0
0
0
0

No
No
No
No
No
No
No
No

____________

1
1
1
1
1
1
1
1

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)

(18)

Hct at presentation
19.

Weight loss in lbs prior to
presentation with index primary
colorectal cancer
(use 999 if unknown)

20.

Weight in lbs at presentation with
index primary colorectal cancer
(use 999 if unknown)

21.

Height in inches
(use 999 if unknown)

22-40.

Charlson Index comorbidities:
Myocardial infarct
Congestive heart disease
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Connective tissue disease
Peptic ulcer disease
Mild liver disease
Diabetes
Hemiplegia
Moderate/severe renal disease
Diabetes w/ end organ disease
Non-metastatic cancer,
other than colon cancer
Metastatic cancer,
other than colon cancer

0
0
0
0
0
0
0
0
0
0
0
0
0
0

No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown
No/unknown

1
1
1
1
1
1
1
1
1
1
1
1
1
1

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

(22)

0

No/unknown

1 Yes

(36)

0

No/unknown

1 Yes

(37)

(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
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Leukemia
Lymphoma
Moderate/severe liver disease
AIDS

41-44.

Smoking history

0
0
0

No/unknown
No/unknown
No/unknown

0

No

1

1 Yes
1 Yes
1 Yes

(38)
(39)
(40)

Yes

2

Unknown

(41)

Packs per day
Years
Pack-years

__________

(42)

__________

(43)

__________

(44)

If any quantity unknown,
specify “999.” Give only
numbers from chart.
45.

History of alcohol use

0

No

1

Yes

2

Unknown

46.

History of
hormone replacement therapy

0

No

1

Yes

2

Unknown

47 - 55.

Personal history of cancer
other than the index primary
colorectal cancer

Cancer #1
________ (47)

Cancer #2
______ (48)

Cancer #3
______ (49)

CODING KEY - additional primary cancers
0
Primary of
5
Urothelium
unknown origin
(renal pelvis,
ureter,
bladder)
1
2nd Colorectal
6
Endometrium
2
Stomach
7
Ovary
3
Small Intestine
8
Brain
4
Ampulla
9
Other
99 None
Cancer #1 ___________________________
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(50)

If cancer is “9 Other,” specify
primary:

Cancer #2 ___________________________
(51)

Cancer #3 ___________________________
(52)

Did the additional primary
cancer coexist with the index
primary colorectal cancer?
Cancer #1
Cancer #2
0
Cancer #3

No

1

Yes

2

Unknown

No

1

Yes

2

Unknown

No

1

Yes

2

Unknown

1

Yes

(53)

0
(54)

0
(55)

56-92.

Family history recorded in chart?

0

Family history of cancer:

Relation
to Patient
#2

2nd
Degree?

_______ (57)
(60)

_____ (58)

_____ (59)

_____

_______ (61)
(64)

_____ (62)

_____ (63)

_____

_______ (65)
(68)

_____ (66)

_____ (67)

_____

_______ (69)
(72)

_____ (70)

_____ (71)

_____

_______ (73)
(76)

_____ (74)

_____ (75)

_____

_______ (77)
(80)

_____ (78) _____ (79)

_____

_______ (81)
(84)

_____ (82) _____ (83)

_____

_______ (85)
(88)

_____ (86)

_____ (87)

_____

_______ (89)
(92)

_____ (90)

_____ (91)

_____

Family member

#1
#2
#3
#4
#5
#6
#7
#8
#9

No

(56)

Primary
Cancer #1

Primary
Cancer

CODING KEY – Relation to Patient
0
Unknown
7
Grandmother
1
Mother
8
Grandfather
2
Father
9
Aunt
3
Sister
10 Uncle
4
Brother
99 No cancer
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5
6

Daughter
Son

CODING KEY - 2nd Degree?
0
1
2

1st degree or unknown
maternal 2nd degree relative
paternal 2nd degree relative

Note: 2nd degree relatives are
grandparents, aunts and uncles
CODING KEY - Primary Cancer
0
Primary of
5
Urothelium
unknown origin
(renal pelvis,
ureter,
bladder)
1
Colorectum
6
Endometrium
2
Stomach
7
Ovary
3
Small Intestine
8
Brain
4
Ampulla
9
Other
93.

Location of index primary
colorectal adenocarcinoma in
patient

1
2
3
4
5

Cecum & Ileocecal Valve
Appendix
Ascending colon (Right colon)
Hepatic flexure of colon
Transverse colon

6

Splenic flexure of colon

7
8
9
10
11
94-97.

TNM tumor stage at time of
surgery for index primary
colorectal cancer

Descending colon (Left colon)
Sigmoid colon
Colon, NOS
Rectosigmoid junction (Rectosigmoid
colon)
Rectum

Primary Tumor (T)

(94)

0

T0 – No evidence of primary tumor

1

T1 – Tumor invades submucosa

2

T2 – Tumor invades muscularis propria

3

T3 – Tumor invades through the
muscularis propria into the subserosa, or
into non-peritonealized pericolic or
perirectal tissues
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4

T4 – Tumor directly invades other organs
or structures, and/or perforates visceral
peritoneum
Note 1: Direct invasion in T4 includes
invasion of other segments of the
colorectum by way of the serosa; for
example, invasion of the sigmoid colon
by a carcinoma of the cecum
Note 2: Tumor that is adherent to other
organs or structures, macroscopically, is
classified as T4

TNM staging (continued)

5

TX – Primary tumor cannot be assessed

6

Tis – Carcinoma in situ; intraepithelial
or invasion of lamina propria
Note: Tis includes cancer cells confined
within the glandular basement membrane
(intraepithelial) or lamina propria
(intramucosal) with no extension through
the muscularis mucosa into the
submucosa

Regional Lymph Nodes (N)

(95)

0

N0 – No regional lymph node metastasis

1

N1 – Metastasis in 1 to 3 regional lymph
nodes

2

N2 – Metastasis in 4 or more regional
lymph nodes

3

NX – Regional lymph nodes cannot be
assessed

Distant Metastasis (M)

(96)

0

M0 – No distant metastasis

1

M1 – Distant metastasis

2

MX – Distant metastasis cannot be
assessed
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Radial Margins and Residual Tumor (R)

98.

Tumor stage at time of surgery
for index primary colorectal
cancer (use TNM classification
to determine stage)

(97)

0

R0 – Complete resection, margins
histologically negative, no residual tumor
left after resection

1

R1 – Incomplete resection, margins
histologically involved, microscopic
tumor remains after resection of gross
disease

2

R2 – Incomplete resection, margins
involved or gross disease remains after
resection

3

Resection margins cannot be assessed

0

Stage 0

Tis

N0

M0

1

Stage I

T1
T2

N0
N0

M0
M0

2

Stage IIA

T3

N0

M0

3

Stage IIB

T4

N0

M0

4

Stage IIIA

T1-T2

N1

M0

5

Stage IIIB

T3-T4

N1

M0

6

Stage IIIC

Any T

N2

M0

7

Stage IV

Any T

Any N

M1
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8

Tumor stage cannot be assessed

Histologic grading of index
primary adenocarcinoma

1
2
3
4
9

G1 – Well differentiated
G2 – Moderately well differentiated
G3 – Poorly differentiated
G4 – Undifferentiated
GX – Grade not determined or unspecified

100.

Histology –
Mucinous component?

0
1

No mucinous component noted
Yes

101.

Histology –
Signet ring cells?

0
1

No signet ring cells noted
Yes

102.

Histology –
Perineural invasion?

0
1

No perineural invasion noted
Yes

103.

Histology –
Lymphatic invasion?

0
1

No lymphatic invasion noted
L – Microscopic lymphatic invasion

104.

Vascular invasion?

0
1
2

No vascular invasion noted
V1 – Microscopic vascular invasion
V2 – Macroscopic vascular invasion

105108.

Metastases present at time of
surgery for index primary
colorectal cancer:

99.

109.

Liver
Lung

0
0

No
No

1
1

Yes
Yes

(105)

Metastasis other than liver or
lung

0

No

1

Yes

(107)

Date of surgery for index
primary colorectal cancer

(106)

Site(s): __________________________

/

(108)

/

(MM/DD/YYYY)
If month or day is unknown,
specify value as 01. If entire
date is unknown, specify value
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as 01/01/1111.
110.

Type of surgery for index
primary colorectal cancer

0
1
2
3
4
5
6
7

Not resected
Subtotal colectomy
Right hemicolectomy
Transverse colectomy
Left hemicolectomy
Sigmoid resection
Low anterior resection (rectal cancer)
Abdominoperineal resection (rectal cancer)

111.

Were resection margins clear
on index primary colorectal
cancer?

0
1
2
3

No
Yes
Primary not resected
Unknown

112113.

Size
of
index
primary
colorectal
cancer
from
pathology report

114115.

Number of nodes taken at
resection of index primary
colorectal cancer
Number of these nodes that
were positive for cancer

116123.

Treatment
for
hepatic
metastasis present at time of
surgery for index primary
colorectal cancer:
Surgical treatment
Wedge resection
Segmentectomy
Lobectomy
Radio frequency ablation
Infusion pump
Timing of this treatment for
hepatic metastasis present at
surgery for index primary
colorectal cancer:

Length along axis of colon _________ cm
(112)

Maximum diameter __________ cm

____________

(114)

____________

(115)

0
0
0
0
0
0

1
1
1
1
1
1

No
No
No
No
No
No

Yes
Yes
Yes
Yes
Yes
Yes

(113)

(116)
(117)
(118)
(119)
(120)
(121)

(122)

0

None of the above treatments done for
hepatic metastasis at time of surgery or later

1

Treatment done at time of surgery
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2

124126.

Treatment for pulmonary
metastases at time of surgery
for index primary colorectal
cancer:
Surgical treatment
Wedge resection
Lobectomy

127.

Preoperative treatment
for index primary
colorectal cancer

Treatment delayed until a later time
Date ______ / ______ / ______

0
0
0

No
No
No

1
1
1

Yes
Yes
Yes

0

None

1

Chemotherapy

2

Radiation therapy

3

Both

(124)
(125)
(126)

128.

Intra-operative radiation therapy at
time of treating index primary?

0

No

129.

Postoperative treatment

0

None

for index primary

1

Chemotherapy

colorectal cancer

2

Radiation therapy

3

Both

0

No

Local
Liver
Lung

0
0
0

No
No
No

1
1
1

Yes
Yes
Yes

(131)

Sites other than liver or lung

0

No

1

Yes

(134)

130.

Recurrence of index primary
colorectal cancer (radiographic)

131135.

Sites of recurrent colorectal
cancer:

Site(s):

1

1

(123)

Yes

Yes

2

Unknown

(132)
(133)

____________________________

(135)

136.

Date recurrence discovered

/

/
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(MM/DD/YYYY)
If month or day is unknown,
specify value as 01. If entire
date is unknown, specify value
as 01/01/1111.
137139.

Treatment of recurrent disease:
Surgical resection

0

No

1

Yes

2

Unknown

No

1

Yes

2

Unknown

No

1

Yes

2

Unknown

(137)

Radio frequency ablation
(RFA)

0
(138)

Chemotherapy
0
(139)

140.

Date of treatment of recurrence
by resection or RFA.

/

/

/

/

If month or day is unknown,
specify value as 01. If entire
date is unknown, specify value
as 01/01/1111.
141.

Date of last recorded contact
with patient in chart
If month or day is unknown,
specify value as 01. If entire
date is unknown, specify value
as 01/01/1111.

142209.

CEA:

Date drawn
______ /______ / ______

Level
(142)

________

(144)

________

(146)

________

(148)

________

(143)

______ /______ / ______
(145)

______ /______ / ______
(147)

______ /______ / ______
(149)
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______ /______ / ______

(150)

________

(152)

________

(154)

________

(156)

________

(158)

________

(160)

________

(162)

________

(164)

________

(166)

________

(168)

________

(151)

______ /______ / ______
(153)

______ /______ / ______
(155)

______ /______ / ______
(157)

______ /______ / ______
CEA (continued)

(159)

______ /______ / ______
(161)

______ /______ / ______
(163)

______ /______ / ______
(165)

______ /______ / ______
(167)

______ /______ / ______
(169)

Level

Date drawn
______ /______ / ______

(170)

________

(172)

________

(174)

________

(176)

________

(178)

________

(180)

________

(182)

________

(184)

________

(186)

________

(188)

________

(190)

________

(192)

________

(171)

______ /______ / ______
(173)

______ /______ / ______
(175)

______ /______ / ______
(177)

______ /______ / ______
(179)

______ /______ / ______
(181)

______ /______ / ______
(183)

______ /______ / ______
(185)

______ /______ / ______
(187)

______ /______ / ______
(189)

______ /______ / ______
(191)

______ /______ / ______
(193)
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______ /______ / ______

(194)

________

(196)

________

(198)

________

(200)

________

(202)

________

(204)

________

(206)

________

(208)

________

(195)

______ /______ / ______
(197)

______ /______ / ______
(199)

______ /______ / ______
(201)

______ /______ / ______
(203)

______ /______ / ______
(205)

______ /______ / ______
(207)

______ /______ / ______
(209)

210.

Second tissue for study:
Note: This tissue cannot be a first colorectal
primary; if second tissue available, then it
should be the next earliest available site

1
2
3
4
5
6
7

none
Second colorectal primary
Local recurrence
Appendiceal adenocarcinoma
Hepatic metastasis
Pulmonary metastasis
Other metastasis:
Site

_________________________

(211)

212.

Date of collection,
second tissue

213.

Surgical Accession Number,
second tissue

214.

Third tissue for study:
Note: This tissue cannot be a first
colorectal primary; if second
tissue available, then it should be
the next earliest available site

/

/

S - ______________________
1
2
3
4
5
6
7

none
Second colorectal primary
Local recurrence
Appendiceal adenocarcinoma
Hepatic metastasis
Pulmonary metastasis
Other metastasis:
Site

_________________________

(215)

216.

Date of collection,
third tissue

/

/
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217.

Surgical Accession Number,
third tissue

S - ______________________
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